CN115518069A - Application of hexahydrobenzophenanthridine alkaloid in dopamine neuron protection - Google Patents
Application of hexahydrobenzophenanthridine alkaloid in dopamine neuron protection Download PDFInfo
- Publication number
- CN115518069A CN115518069A CN202211318400.8A CN202211318400A CN115518069A CN 115518069 A CN115518069 A CN 115518069A CN 202211318400 A CN202211318400 A CN 202211318400A CN 115518069 A CN115518069 A CN 115518069A
- Authority
- CN
- China
- Prior art keywords
- compound
- hexahydrobenzophenanthridine
- hexahydro
- alkaloid
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 210000002569 neuron Anatomy 0.000 title claims abstract description 20
- 229960003638 dopamine Drugs 0.000 title claims abstract description 11
- UXUNBLONJMOCEN-UHFFFAOYSA-N 1,2,3,4,4a,5-hexahydrobenzo[k]phenanthridine Chemical class C1=CC=C2C=CC3=CNC(CCCC4)C4=C3C2=C1 UXUNBLONJMOCEN-UHFFFAOYSA-N 0.000 title abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 26
- 241000252212 Danio rerio Species 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 18
- 241000471262 Ardisia japonica Species 0.000 abstract description 15
- 208000018737 Parkinson disease Diseases 0.000 abstract description 13
- 238000000605 extraction Methods 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 208000007536 Thrombosis Diseases 0.000 abstract description 11
- -1 alkaloid compounds Chemical class 0.000 abstract description 9
- 238000000926 separation method Methods 0.000 abstract description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 229930013930 alkaloid Natural products 0.000 abstract description 7
- 229910000365 copper sulfate Inorganic materials 0.000 abstract description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 abstract description 5
- 229940114079 arachidonic acid Drugs 0.000 abstract description 4
- 235000021342 arachidonic acid Nutrition 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 230000000706 effect on dopamine Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000003208 petroleum Substances 0.000 description 17
- 238000010828 elution Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 241000251468 Actinopterygii Species 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- GHKISGDRQRSCII-ZOCIIQOWSA-N chelidonine Chemical compound C1=C2[C@H]3N(C)CC4=C(OCO5)C5=CC=C4[C@H]3[C@@H](O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-ZOCIIQOWSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 230000002785 anti-thrombosis Effects 0.000 description 8
- 239000000287 crude extract Substances 0.000 description 8
- 230000000366 juvenile effect Effects 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 7
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- GHKISGDRQRSCII-UHFFFAOYSA-N chelidonine Natural products C1=C2C3N(C)CC4=C(OCO5)C5=CC=C4C3C(O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-UHFFFAOYSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000002027 dichloromethane extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 4
- 241000722824 Ardisia crenata Species 0.000 description 4
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002021 butanolic extract Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- 238000009372 pisciculture Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical class C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229930015421 benzophenanthridine alkaloid Natural products 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JEUXZUSUYIHGNL-UHFFFAOYSA-N n,n-diethylethanamine;hydrate Chemical compound O.CCN(CC)CC JEUXZUSUYIHGNL-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241001361205 Dactylicapnos Species 0.000 description 1
- 244000117040 Dactylicapnos scandens Species 0.000 description 1
- 241001488541 Dactylicapnos torulosa Species 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 241001098657 Pterois Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OWUNMSGLMUPGEZ-UHFFFAOYSA-N benzo[k]phenanthridine Chemical compound C1=CC=CC2=C3C4=CC=CC=C4C=CC3=CN=C21 OWUNMSGLMUPGEZ-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 101150064356 incD gene Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000004177 patent blue V Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Abstract
The invention provides application of hexahydro-benzophenanthridine alkaloids in dopamine neuron protection, and belongs to the technical field of biological medicines. The invention firstly takes ardisia japonica of fruits as a raw material, obtains two high-purity hexahydro benzophenanthridine alkaloids by extraction, separation and purification, and tests prove that the hexahydro benzophenanthridine alkaloids have an inhibition effect on thrombus caused by arachidonic acid, an inhibition effect on zebra fish inflammation caused by copper sulfate and a strong protection effect on dopamine neurons, which indicates that the alkaloid compounds can be novel and effective medicines for treating heart Parkinson diseases and have good practical application value.
Description
The application is a divisional application with the title of hexahydro benzophenanthridine alkaloids, preparation method and application, namely application number 2021105224812, application date 2021, 5 months and 13 days.
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of hexahydrobenzophenanthridine alkaloids in dopamine neuron protection.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
Ardisia japonica (Dactylicapnos torulosa) is a poppy family purple plant, an annual herb, and currently, only found in the southwest, the west, the middle to the southeast of Yunnan, the west of Guizhou, the southwest of Sichuan, and the southeast of Tibet in China. Under natural state, the plant grows under forests, bushes or ditch sides and roadside at the elevation of 1-3 000m. The main active ingredients in the ardisia crenata sims contain alkaloids, and have the activities of regulating cardiovascular system, relieving pain, relieving spasm, protecting liver, resisting anoxia, resisting malaria, etc. The ardisia japonica has complex chemical components and difficult active component separation, and few reports exist for separating specific high-purity hexahydrobenzophenanthridine alkaloids.
Inflammation also plays a major role in many epidemic conditions, such as alzheimer's disease, parkinson's, liver and lung cancer. In developed or developing countries, the neurodegenerative disease Parkinson's Disease (PD), caused by inflammation, is a serious threat to human health and human well-being. Parkinson's disease is one of the extrapyramidal diseases of the middle-aged and the elderly, also called paralysis agitans, is the second major nervous system disease which is second to Alzheimer's disease at present, has a chronic progressive disease course, has no effective prevention method, and can increase the morbidity by times along with the increase of age.
It has been reported that protopine, a component of dactylicapnos scandens, inhibits the 5-hydroxytryptamine transporter and the norepinephrine transporter and has an antidepressant effect in a mouse model, suggesting that they may improve neurodegenerative disease activity. Promotopine also has an effect on the release of platelet active substances that are affected by platelet aggregation, suggesting possible antithrombotic activity. The inventor finds that the predecessor only carries out systematic research on pain easing and cardiovascular effects of dactylicapnos. The benzophenanthridine alkaloid compounds in the ardisia japonica and the medical biological activity thereof are rarely reported.
Disclosure of Invention
Based on the defects of the prior art, the hexahydrobenzophenanthridine alkaloids and the preparation method and the application thereof are provided, the ardisia crenata sims is used as a raw material for the first time, two high-purity hexahydrobenzophenanthridine alkaloids are obtained through extraction, separation and purification, and experiments prove that the hexahydrobenzophenanthridine alkaloids have an inhibition effect on thrombus caused by arachidonic acid, have an inhibition effect on zebra fish inflammation caused by copper sulfate and have a strong protection effect on dopamine neuron, so that the alkaloid compounds can be novel and effective medicines for treating heart Parkinson diseases and have good practical application value.
In a first aspect of the invention, there is provided a compound of formula (I):
wherein R may be selected from OCH 3 Or H;
when R is selected from OCH 3 When this is compound 1: 4-methoxycholeridine;
when R is selected from H, the compound is the compound 2: chelidonine.
In some embodiments of the present invention, hexahydrobenzophenanthridine alkaloids of formula (I) may be prepared in crystalline or amorphous form, and if crystalline, may optionally be solvates, for example as hydrates.
In a second aspect of the present invention, there is provided a process for the preparation of the above compound, which process comprises:
s1, adding ethanol into ardisia japonica, soaking and extracting, and combining concentrated extracting solutions to obtain a crude extract;
s2, suspending the crude extract in diluted hydrochloric acid, performing suction filtration to obtain a filtrate, adjusting the pH to be alkaline, and sequentially extracting by using petroleum ether, dichloromethane and n-butanol;
s3, separating the dichloromethane extract by a silica gel column, performing gradient elution by using dichloromethane-methanol with a gradient of 200 to 1;
and S4, treating the n-butanol extract by an MCI column, performing gradient elution by using methanol-water with a gradient of 1.
In a third aspect of the invention, there is provided the use of a compound as described above in any one or more of:
a) Inhibiting thrombosis and/or preparing medicines related to inhibiting thrombosis;
b) Inhibiting inflammatory reaction and/or preparing medicaments related to the inhibition of inflammatory reaction;
c) (ii) protection of dopamine neurons and/or protection of dopamine neuron-related drugs;
d) Treating cardiac Parkinson's disease and/or preparing medicine for treating cardiac Parkinson's disease.
In a fourth aspect of the invention, there is provided a method of treating cardiac parkinson's disease, said method comprising administering to a subject a therapeutically effective amount of a compound as described above.
The beneficial technical effects of one or more technical schemes are as follows:
according to the technical scheme, the two hexahydrobenzophenanthridine alkaloids are simultaneously separated and efficiently obtained from the ardisia crenata sims, so that the comprehensive utilization of natural medicine resources is realized, and an effective way is provided for searching for new medicine active ingredients.
Meanwhile, through the test experiment and the structure-activity relationship research on the anti-inflammatory, antithrombotic and MPTP-induced Parkinson activity of the alkaloid compound separated from ardisia japonica, the result shows that hexahydrobenzophenanthridine alkaloid has an inhibition effect on the thrombus caused by arachidonic acid, has an inhibition effect on the inflammation of zebrafish caused by copper sulfate and has a strong protection effect on dopamine neurons, and the alkaloid compound is possibly a novel and effective medicament for treating the cardiac Parkinson disease, so that the alkaloid compound has a good practical application prospect.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, are included to provide a further understanding of the invention, and are incorporated in and constitute a part of this specification, illustrate exemplary embodiments of the invention and together with the description serve to explain the invention and not to limit the invention.
FIG. 1 is a HR-ESI-MS spectrum of 4-methoxycyclidine isolated by an example of the present invention.
FIG. 2 shows 4-methoxycyclidine isolated by the present invention 1 HNMR atlas (600MHz, in CD 3 OD)。
FIG. 3 is a schematic representation of 4-methoxyehelidonine isolated according to an embodiment of the present invention 13 CNMR atlas (400MHz, in CD 3 OD)。
FIG. 4 is an HSQC spectrum (400MHz, in CD) of 4-methoxyhedonine isolated in the examples of the present invention 3 OD)
FIG. 5 is an HMBC profile of 4-methoxychelidonine isolated in accordance with an embodiment of the present invention (400MHz, incD) 3 OD)。
FIG. 6 shows (+) -chelidonine isolated according to an embodiment of the invention 1 HNMR map (600MHz, in CDCl 3 )。
FIG. 7 shows (+) -chelidonine isolated according to an embodiment of the invention 13 CNMR map (400MHz, in CDCl 3 )。
FIG. 8 shows the results of experiments conducted by compounds 1 and 2 of the present invention at 3 different concentrations to inhibit inflammation induced by copper sulfate in zebra fish; wherein, a is an experimental map of inflammatory response, and b is a statistical map of experimental data.
FIG. 9 shows the results of the determination of antithrombotic activity of compounds 1 and 2 of the example of the present invention at 3 different concentrations; wherein, a is an experimental chart of antithrombotic activity, and b is a statistical chart of experimental data.
FIG. 10 is the results of the dopamine neuron protective assay for compounds 1 and 2 according to the example embodiments of the present invention; wherein a is a length statistical chart of each group of DA neurons; b is a diagram of the condition of DA neurons of the juvenile fish observed by each group of fluorescence microscopes; and c is a motion trail diagram of each group of zebra fishes.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments in accordance with the present application. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
As mentioned above, the benzophenanthridine alkaloid compounds in the ardisia japonica and the medical biological activity thereof are rarely reported at present.
In view of the above, in one exemplary embodiment of the present invention, there is provided a benzophenanthridine alkaloid compound represented by formula (I):
wherein R may be selected from OCH 3 Or H;
when R is selected from OCH 3 When this is compound 1: 4-methoxycholeridine;
when R is selected from H, the compound is the compound 2: chelidonine.
In some embodiments of the invention, hexahydrobenzophenanthridine alkaloids of formula (I) may be prepared in crystalline or amorphous form, and if crystalline, may optionally be solvates, for example as hydrates.
In another embodiment of the present invention, there is provided a method for preparing the above compound, comprising:
s1, adding ethanol into ardisia japonica, soaking and extracting, and combining concentrated extracting solutions to obtain a crude extract;
s2, suspending the crude extract in diluted hydrochloric acid, performing suction filtration to obtain a filtrate, adjusting the pH to be alkaline, and sequentially extracting by using petroleum ether, dichloromethane and n-butanol;
s3, separating the dichloromethane extract by a silica gel column, performing gradient elution by using dichloromethane-methanol with gradient of 200 to 1;
and S4, treating the n-butanol extract by an MCI column, performing gradient elution by using methanol-water with a gradient of 1.
The extraction preparation method gradually separates high-purity monomer components of the compound from Ardisia japonica in a coarse-fine mode.
The gradient elution in the present invention refers to that the concentration ratio of the mobile phase is constantly changed during the elution process, but the initial concentration and the final concentration are fixed, for example, "performing gradient elution with dichloromethane-methanol with a gradient of 200: the dichloromethane-methanol was subjected to gradient elution in such a manner that the starting volume ratio was 200 and the elution end volume ratio was 1.
The individual steps of the preparation process of the invention can be further improved, for example:
in still another embodiment of the present invention, in the step S1,
in the step S1, the raw materials of the ardisia japonica comprise underground parts and overground parts of the ardisia japonica;
the solvent and feed liquid used for extraction have influence on the impurity content of the crude extract and the extraction rate of the effective components. The solvent is preferably a 90 to 95% ethanol solution, and more preferably a 95% ethanol solution. The feed liquid ratio of the ardisia japonica and the ethanol is 1kg: 2-7L (preferably 1.06kg: 3L). More specifically, the leaching is carried out by a multiple leaching process. The extraction conditions are adopted to effectively reduce the content of impurities in the crude extract, thereby further improving the extraction rate of hexahydro benzophenanthridine alkaloids.
In still another embodiment of the present invention, in the step S2,
the dilute hydrochloric acid is 0.5% -5% and the concentration of the hydrochloric acid is controlled to be 0.5%, 1%, 2%, 3% or 5%;
in the step of adjusting the pH to be alkaline, the pH of the filtrate is adjusted to 9-12 by using 20-30% ammonia water.
The specific method for sequentially extracting by using petroleum ether, dichloromethane and n-butanol comprises the following steps:
adding petroleum ether, standing and extracting for 10-30 min, collecting supernatant, namely extracting solution, recovering the petroleum ether under reduced pressure at 40-50 ℃, using the recovered petroleum ether for extraction again until the color of the finally obtained extracting solution is light green, and recovering the petroleum ether under reduced pressure to obtain petroleum ether extract; sequentially extracting dichloromethane and n-butanol according to the extraction process of petroleum ether to obtain dichloromethane extract and n-butanol extract respectively;
in still another embodiment of the present invention, in the step S3,
the specific procedure of gradient elution with dichloromethane-methanol is as follows: volume ratio of dichloromethane to methanol =200, 1, 180; by adopting the optimized gradient condition, the separation degree can be improved;
further, TLC thin-layer chromatography and mass spectrum tracking detection are adopted, fractions mainly containing target components are collected and concentrated, the obtained extract silica gel thin-layer detection is carried out, and similar components are combined to obtain 8 components, namely S1-S8; the S3 fraction was subjected to liquid chromatography (1.5 mL/min, meOH-H) 2 O (0.1-tea) 77) to obtain the compound 1, i.e., 4-methoxycyclidine (t) R ＝28.0min)；
The liquid chromatography parameters were as follows:
a chromatograph: agilent 1260-DAD;
a chromatographic column: agilent YMC-Pack ODS-AS-5 μm,12nm (250 mm. Times.10 mm) -C18;
the eluent is: mobile phase B methanol, mobile phase a 0.1% triethylamine water, flow rate: 1.5mL/min of the reaction solution,
isocratic elution: 0 to 15min, B:77vol%, A:23vol%.
The compound 1 with high purity can be directly obtained by adopting the liquid chromatography separation.
In still another embodiment of the present invention, in the step S4,
performing gradient elution by using methanol and water, wherein the specific procedure of the gradient elution is as follows: methanol to water volume ratio =1, 2, 3, 2, 4.
Further, fractions mainly containing the target component were collected by TLC thin layer chromatography and mass spectrometric follow-up detection to obtain 4 fractions (3I 1 to 3I 4). 3I4 gradient elution with methanol and water as eluent (V/V = 3; separation by ODS column gave 9 fractions (3I 4O1 → 3I4O 9). The compound 2, i.e., chelidonine, is obtained by recrystallization from 3I4O 5.
In a further embodiment of the invention, there is provided the use of a compound as described above in any one or more of:
a) Inhibiting thrombosis and/or preparing medicines related to inhibiting thrombosis;
b) Inhibiting inflammatory reaction and/or preparing medicaments related to the inhibition of inflammatory reaction;
c) (ii) protecting dopamine neurons and/or dopamine neuron-related drugs;
d) Treating cardiac Parkinson's disease and/or preparing medicine for treating cardiac Parkinson's disease.
In yet another embodiment of the present invention, there is provided a method of treating cardiac parkinson's disease, said method comprising administering to a subject a therapeutically effective amount of a compound as described above.
The subject of the present invention refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
A therapeutically effective amount according to the present invention is that amount of active compound or pharmaceutical agent, including a compound of the present invention, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other medical professional, which response includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition or disorder being treated.
The range of therapeutically effective amounts that can be used will be known to the researcher, veterinarian, medical doctor or other medical professional in the art based on clinical trials or other means known in the art.
The invention is further illustrated by the following examples, which are not to be construed as limiting the invention thereto. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Examples extraction separation experiments
1) Twisting fruit ardisia japonica raw materials (10.6 Kg: extracting 1.1Kg of root and 9.5Kg of aerial part with 95% ethanol (3 × 30L, first 7 days, second 10 days, and third 3 days) by cold liquid immersion, mixing the three extractive solutions, and concentrating the extractive solution with large rotary evaporator (55 deg.C in water pot and-0.06 MPa in vacuum) of Zyguyi Yuhua apparatus GmbH to obtain 500g of crude extract. Suspending part of the crude extract (483.2 g) in 1% diluted hydrochloric acid (3L), suction filtering to obtain filtrate, adjusting pH of the filtrate to 10 with 25% ammonia water, sequentially extracting with petroleum ether (3 × 3L) to obtain PE extract (1.7 g), and extracting with CH 2 Cl 2 (800mL, 700mL,800mL and 700 mL) to give CH 2 Cl 2 Extract (3.9 g), using n-BuOH (400 mL, 300mL and 300 mL) to give a nBuOH extract (5.6 g), leaving an aqueous layer fraction (140.3 g).
Specifically, the extraction steps using petroleum ether, dichloromethane and n-butanol include: adding petroleum ether, standing and extracting for 10-30 min, collecting supernatant, namely extracting solution, recovering the petroleum ether under reduced pressure at 55 ℃, reusing the recovered petroleum ether for extraction until the color of the finally obtained extracting solution is light green, and recovering the petroleum ether under reduced pressure to obtain petroleum ether extract; and sequentially extracting dichloromethane and n-butanol according to the extraction process of petroleum ether to obtain dichloromethane extract and n-butanol extract respectively. The ingredients in the ardisia japonica thunb extract are complex, and the primary separation and enrichment of the effective ingredients are realized by adopting organic solvents with sequentially increased polarities.
2) Mixing a dichloromethane extract (3.7 g) and silica gel, loading the mixture into a column, performing gradient elution by using a dichloromethane-methanol system, wherein the dichloromethane-methanol volume ratio is = 10. Gradient V/V =200, 1, 150. And S3, separating by adopting high performance liquid chromatography.
Liquid chromatography parameters: chromatograph: agilent 1260-DAD;
and (3) chromatographic column: agilent YMC-Pack ODS-AS-As-5 μm,12nm (250 mm. Times.10 mm); the eluent is: the mobile phase B is methanol, the mobile phase A is 0.1 percent (mass percent) of triethylamine water, and the flow rate is as follows: 1.5mL/min, isocratic elution: 0 to 15min, B:77vol%, A:23vol%. S3 can be directly separated by liquid chromatography to obtain high-purity 4-methoxychelidonine (t) R ＝28.0min)。
3) The nBuOH extract (5.6 g) was passed through an MCI column, eluted successively with methanol and water, followed by detection by TLC thin layer chromatography and mass spectrometry, to collect a fraction mainly containing the objective component, followed by separation with methanol and water as an eluent through an ODS column, and then by recrystallization to obtain Compound-chelidonine.
Specifically, a methanol-water system is adopted for gradient elution, the volume ratio of methanol to water is = 1. Gradient elution was performed on 3I4 using reverse silica gel as a packing material (50 × 300 mm) and a methanol-water system as an eluent (V/V =3: 1), one fraction per 100mL of eluent, a total of 165 fractions were collected, similar fractions were combined according to TLC and uv-coloration (254 nm or 365 nm), and the solvent was recovered under reduced pressure to give a total of 9 fractions (3I 4O1 to 3I4O 9). 3I4O5 recrystallization to obtain (+) -chelidonine.
Effect verification
Experimental example 1:
the experiment establishes an inflammation model of the fluorescent transgenic zebra fish (Tg: zlyz-EGFP) stimulated by copper sulfate, counts the migration quantity of macrophages, screens the anti-inflammatory activity of hexahydrobenzophenanthridine alkaloid compounds with a general formula (I), and observes whether the compounds separated from Ardisia japonica have the anti-inflammatory potential.
Anti-inflammatory activity assay:
the activity test method is as follows:
healthy inflammatory cell fluorescent transgenic zebra fish fertilized with 72hpf is taken as an experimental animal, and is randomly divided into a sample treatment group, a model group, a blank control group and a positive control group (20 mu M ibuprofen) to be tested, wherein the sample treatment group is 5, 10 and 25 mu M, 10 embryos are arranged in each group, 2 multiple wells are simultaneously arranged, and each concentration is repeated for three times. All the groups are put into a constant temperature incubator at 28.5 ℃ for co-culture for 2h. Then using 20 mu M CuSO 4 The zebra fish of each sample group and the positive control group are respectively treated for 1h. After treatment, the zebra fish is cleaned, then inflammatory reaction is observed under a fluorescence microscope, the number of inflammatory cells migrating to the zebra fish test line is calculated, and GraphPad software statistically analyzes all groups of data.
The results of the activity assay are shown in FIG. 8.
Among alkaloids, compound 2 has the best anti-inflammatory activity; the number of the Proepoxy methylene and the methoxyl and the position of the methoxyl influence the activity of the compound, and the methoxyl at the 4-position can weaken the activity of the compound; when the benzophenanthridine is 25 mu M, the anti-inflammatory activity is as follows: 2 >.
Experimental example 2:
the experiment establishes a thrombus model of wild zebra fish (AB) stimulated by arachidonic acid, counts the red dyeing area of the heart, screens the antithrombotic activity of hexahydrobenzophenanthridine alkaloid compounds with the general formula (I), and observes whether the compound separated from ardisia crenata has the antithrombotic potential.
Antithrombotic activity test:
the activity test method is as follows:
taking 72hpf wild type zebrafish embryos in a culture dish, selecting the embryos which are normally developed under a stereomicroscope, transferring the embryos into a 24-well culture plate, wherein 10 embryos are contained in each well, and each concentration is 2 multiple wells. Setting experimental groups, namely a solvent control group and a model group: adding 0.4% (w/w) DMSO solution, and after 6 hr, changing to 80 μ M AA solution; positive control group: adding ASP solution to make the final concentration 22.5 μ g/mL, placing in 28 deg.C incubator for 6h, and changing to AA solution with final concentration of 80 μ M; drug intervention group: adding the drug mother liquor to make the final concentration at 5, 10 and 50 μ M, placing in 28 deg.C incubator for 6h, and changing to AA solution with final concentration of 80 μ M. Then, the mixture was placed in an incubator at 28 ℃ for 1.5 hours. Taken out, and stained with 1mg/mL o-dianisidine staining solution for 10min in a dark place. Washing fish with water for 3 times, and taking pictures.
The results of the activity assay are shown in FIG. 9.
As seen from table 1, the positive control group (aspirin) prevented thrombus rate of 67.4%; the antithrombotic activities of the compounds 1 and 2 showed concentration dependence, and the thrombus-preventing rate of the compound 2 at 10. Mu.M was 76.5%.
TABLE 1 Compounds 1 and 2 prevent thrombosis Rate
Experimental example 3: experiment of protective action of benzophenanthridine alkaloid compound with general formula (I) on dopamine neuron
1) Preparation of zebra fish embryos: when eggs are collected, firstly selectively mature zebra fish are separately placed into an egg laying tank with a partition plate at 5-6 pm according to the male-female ratio of 1; the morning of the next day is 8:30, extracting the partition plate, collecting fertilized eggs after 2 hours, repeatedly washing the fertilized eggs with fresh fish culture water for 3 times, transferring the fertilized eggs into fresh culture water containing 2mg/L methylene blue, and then placing the fresh culture water in an incubator at 28 ℃ for incubation.
2) Grouping and processing of experiments: the transgenic zebra fish Vmat at 1dpf after fertilization, GFP and wild zebra fish AB embryo are subjected to membrane removal treatment by using 1mg/mL Pronase E 131 Then fresh fish-farming water is usedAfter 3 times of cleaning, the fish are placed in a 6-hole plate, 30 juvenile fishes are placed in each hole, and the following experimental groups are set up: 5mL of a control group treated with fresh fish-farming water, 5mL of a group treated with MPTP at a concentration of 50. Mu.M, and 5mL of a group co-treated with MPTP at different concentrations (5. Mu.M, 10. Mu.M, 50. Mu.M) of the compound of Table 4.2 and 50. Mu.M were added (the compound and MPTP were added simultaneously to fresh fish-farming water to respective working concentrations). GFP in transgenic zebra fish is dosed with fresh fish-farming water containing 0.03mg/mL of PTU, which can inhibit melanin generation and facilitate observation of DA neurons. Adding medicine, culturing in 28 deg.C incubator, and changing the medicine every 24 hr.
3) Observation of DA neurons: at 4dpf, randomly selecting 8 juvenile fishes from different experimental groups of transgenic zebra fish Vmat: GFP, observing DA neuron conditions of the juvenile fishes by using a Zeiss stereofluorescence microscope respectively, and photographing and recording.
4) Behavioral experiments: and at 5dpf, randomly selecting 8 juvenile fishes from different experimental groups of the wild zebra fish AB, putting the juvenile fishes into a 48-hole plate, putting one juvenile fish in each hole, adding 1mL of fresh fish culture water, putting the 48-hole plate into a dark box of a Zebrabox zebra fish behavior analyzer for 15min, and starting to perform behavioral detection after the juvenile fishes adapt to the environment. Zeblab software is used for collecting the motion trail of the zebra fish within 20min, and the software is used for exporting data and calculating the total distance.
The ratio of the length of the DA neuron region to the control for the positive drug at 10. Mu.M was 1.29, and the ratios of compound, 1 (5. Mu.M), 1 (10. Mu.M) and 2 (10. Mu.M) were 1.41,1.28 and 1.21, respectively. Among them, the DA protection of the novel compound 1 (5. Mu.M) is the strongest.
Finally, it should be noted that, although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments described in the foregoing embodiments, or equivalents may be substituted for elements thereof. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention. Although the present invention has been described with reference to the specific embodiments, it should be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (1)
1. The application of the compound 4-methoxychelidonine in preparing dopamine neuron related medicines;
the structural formula of the compound 4-methoxycyclidine is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211318400.8A CN115518069B (en) | 2021-05-13 | 2021-05-13 | Application of hexahydrobenzophenanthridine alkaloids in protecting dopamine neurons |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211318400.8A CN115518069B (en) | 2021-05-13 | 2021-05-13 | Application of hexahydrobenzophenanthridine alkaloids in protecting dopamine neurons |
| CN202110522481.2A CN113372355B (en) | 2021-05-13 | 2021-05-13 | Hexahydrobenzophenanthridine alkaloid and preparation method and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110522481.2A Division CN113372355B (en) | 2021-05-13 | 2021-05-13 | Hexahydrobenzophenanthridine alkaloid and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115518069A true CN115518069A (en) | 2022-12-27 |
| CN115518069B CN115518069B (en) | 2023-11-03 |
Family
ID=77570877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211318400.8A Active CN115518069B (en) | 2021-05-13 | 2021-05-13 | Application of hexahydrobenzophenanthridine alkaloids in protecting dopamine neurons |
| CN202110522481.2A Active CN113372355B (en) | 2021-05-13 | 2021-05-13 | Hexahydrobenzophenanthridine alkaloid and preparation method and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110522481.2A Active CN113372355B (en) | 2021-05-13 | 2021-05-13 | Hexahydrobenzophenanthridine alkaloid and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN115518069B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040097533A1 (en) * | 2001-05-11 | 2004-05-20 | Jae-Soon Eun | Pharmaceutical compositions comprising chelidonine or derivatives thereof |
| EP1459753A1 (en) * | 2003-03-18 | 2004-09-22 | Nowicky, Wassyl, Dipl.-Ing. DDr. | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments |
| CN102215840A (en) * | 2008-08-27 | 2011-10-12 | 纽约市哥伦比亚大学托管会 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11310530A (en) * | 1998-04-30 | 1999-11-09 | Maruho Co Ltd | Nitrogen monoxide production inhibitor |
| DE10394363D2 (en) * | 2003-11-05 | 2006-09-21 | Zoser B Salama | New chelidonine derivatives, process for their preparation and their use for the preparation of pharmaceutical active ingredients |
| EP3207048A4 (en) * | 2014-10-17 | 2018-05-30 | The Broad Institute, Inc. | Compositions and methods of treating muscular dystrophy |
-
2021
- 2021-05-13 CN CN202211318400.8A patent/CN115518069B/en active Active
- 2021-05-13 CN CN202110522481.2A patent/CN113372355B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040097533A1 (en) * | 2001-05-11 | 2004-05-20 | Jae-Soon Eun | Pharmaceutical compositions comprising chelidonine or derivatives thereof |
| EP1459753A1 (en) * | 2003-03-18 | 2004-09-22 | Nowicky, Wassyl, Dipl.-Ing. DDr. | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments |
| CN102215840A (en) * | 2008-08-27 | 2011-10-12 | 纽约市哥伦比亚大学托管会 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113372355A (en) | 2021-09-10 |
| CN115518069B (en) | 2023-11-03 |
| CN113372355B (en) | 2023-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105920064A (en) | Natural active ingredient extracted and separated from leaves and stems of panax quinuefolium L and application of natural active ingredient | |
| CN111228254A (en) | Application and preparation method of phenolic compound ZKYY-041 | |
| CN113372355B (en) | Hexahydrobenzophenanthridine alkaloid and preparation method and application thereof | |
| Ballio et al. | Occurrence of fusicoccin in plant tissues infected by Fusicoccum amygdali del | |
| CN111228246A (en) | Application and preparation method of terpene phenol | |
| CN108774282B (en) | Dammarane type triterpene saponin with anti-Alzheimer disease effect in herba Gynostemmatis | |
| CN112194698A (en) | Triterpenoid compound and preparation method and application thereof | |
| CN106939031B (en) | A kind of spirosolane type glycoalkaloid and preparation method thereof and purposes | |
| CN106928309B (en) | A kind of spirosolane type glycoalkaloid and preparation method thereof and purposes | |
| CN105646619B (en) | One kind two caffeoyl spermidines cyclisation derivative and application thereof | |
| CN110204589B (en) | Effective component of feather cockscomb seed, extraction method and application thereof in preparing neuroprotective medicament | |
| CN112194697B (en) | Novel triterpenoid and application thereof in preparation of medicine for treating cardiovascular diseases | |
| CN108129538B (en) | Method for extracting antibacterial compound from scorpion | |
| CN113354643A (en) | Huperzine compound, preparation method and application thereof | |
| CN113717105A (en) | Diterpene alkaloid type compound and extraction method and application thereof | |
| CN111184710A (en) | Application and preparation method of cyclic phenol | |
| CN106349021B (en) | Compound in reineckea carnea and preparation and application thereof | |
| CN107789429A (en) | The isolation and purification method of bacopa monnieri total saponin extracts and its application in drugs for nervous is prepared | |
| CN110559307A (en) | albizzia julibrissin new lignan compound and new application thereof | |
| CN105418725B (en) | Pentacyclic triterpenoid and its application | |
| CN113480557B (en) | Polyketone compounds, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN108314618A (en) | The medical usage of sesquiterpenoids and extracting method and anti-alzheimer's disease | |
| CN108822175B (en) | 3, 16-androstenedione compound and application thereof | |
| CN112194568B (en) | Long-chain triterpenoid compound and preparation method and application thereof | |
| CN104398532B (en) | Application of cardiac glycoside compound 12beta-hydroxycalotropin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230627 Address after: 250012 No. 44 West Wenhua Road, Lixia District, Shandong, Ji'nan Applicant after: SHANDONG University Applicant after: BIOLOGY INSTITUTE OF SHANDONG ACADEMY OF SCIENCES Address before: 250012 No. 44 West Wenhua Road, Lixia District, Shandong, Ji'nan Applicant before: SHANDONG University |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |